000			02215cam a2200349 a 4500
003			EG-GiCUC
005			20250223031213.0
008			150414s2014 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.11.28.M.Sc.2014.Hu.E
100	0		_aHussein Nabil Abdallah
245	1	0	_aEarly versus late indomethacin treatment for patent ductus arteriosus in premature infants / _cHussein Nabil Abdallah ; Supervised Mohamed Fawzan Shaltout , Mohamed Ahmed Aboulhassan , Alaa Eldin Adel Sobeih
246	1	5	_aالمقارنة بين الاستخدام المبكر والمتأخر لعقار الاندوميثاسين لغلق القناة الشريانية فى الأطفال المبتسرين
260			_aCairo : _bHussein Nabil Abdallah , _c2014
300			_a98 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Pediatrics
520			_aPatent ductus arteriosus is a postnatal communication, usually between the main pulmonary trunk and the descending thoracic aorta. The clinical consequences of PDA are related to the magnitude of the left-to-right shunt through the PDA with its associated change in blood flow to the lung, kidneys, and intestine, leading to tachypnea, apnea, CO2 retention and increased need to mechanical ventilation. Indomethacin is the only non-selective cyclooxygenase inhibitor approved by FDA for the treatment of PDA. It has been clearly established both by observational studies and randomized trials that indomethacin increases the rate of PDA closure within 24 hours of its administration. Less clearly established are the optimal timing, dose, and duration of treatment
530			_aIssued also as CD
653		4	_aArteriosus
653		4	_aIndomethacin
653		4	_aPremature infants
700	0		_aAlaa Eldin Adel Sobeih , _eSupervisor
700	0		_aMohamed Ahmed Aboulhassan , _eSupervisor
700	0		_aMohamed Fawzan Shaltout , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aSoheir _eCataloger
942			_2ddc _cTH
999			_c50410 _d50410